Healthgen Announces Listing on October 28, 2025
On the morning of October 28, 2025, Wuhan Healthgen Biotechnology Corp. (Stock Name: Healthgen Biotech; Stock Code: 688765) was officially listed on the Shanghai Stock Exchange, marking its status as the first listed company specializing in recombinant human albumin.
Founded in 2006, Healthgen is an innovative biopharmaceutical enterprise committed to the research and development of recombinant protein-based therapeutics. The company has pioneered a unique Rice Expression System, underpinned by two core platforms: the OryzHiExp (rice endosperm-based protein expression platform) and OryzPur (protein purification platform). These cutting-edge platforms have empowered Healthgen to overcome key challenges in molecular pharming, establishing a comprehensive R&D and production system capable of undertaking national-level projects such as the National High-Tech R&D Program (863 Program) and National Science and Technology Major Projects. The company’s technological achievements have been widely acclaimed, earning honors including the Second-Class National Technology Invention Award, National Excellent Patent Award, and First-Class Hubei Provincial Invention Award (twice). Its innovations are protected by over 80 patents globally. In 2024, Healthgen was featured by CCTV-2 (Finance Channel) as a typical case of "New Quality Productive Forces."
After 20 years of pioneering innovation and independent R&D, Healthgen achieved a milestone in July 2025 when its flagship product, "Recombinant Human Albumin Injection (Oryza Sativa)," received official approval from the National Medical Products Administration (NMPA) of China. As the world’s first fully regulatory-approved recombinant human albumin injection, this product ends the long-standing reliance on human plasma extraction for albumin supply. This breakthrough solidifies China’s leading position in both recombinant human albumin technology and plant-based biomanufacturing, poised to reshape the global biopharmaceutical landscape.
Currently, Healthgen operates an intelligent production line with an annual capacity of 1 million doses of its albumin injection. Additionally, the company broke ground on a new manufacturing facility in 2024, designed to produce 12 million doses annually, with commercial production scheduled to start in 2026. Once operational, the new plant will not only reduce China’s long-term dependence on imported albumin to realize import substitution but also meet national strategic demands and cater to the growing health needs of the public.
